<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:06:06Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/30253" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/30253</identifier><datestamp>2026-09-24T06:27:16Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Bramson, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Adeel, Zoya</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-09-30T14:00:53Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2024-09-30T14:00:53Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/30253</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/13843</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Background: Chimeric antigen receptor (CAR) T cell therapy enlists genetic&#xd;
engineering to express a tumour targeting synthetic receptor on a patient’s T cells.&#xd;
While endogenous T cells rely on costimulatory signals for their development but&#xd;
not their effector function, CAR T cells are completely reliant on costimulatory&#xd;
domains incorporated within the CAR structure to promote T cell expansion and&#xd;
persistence in vivo, resulting in enhanced anti-tumour activity. Toxicities following&#xd;
CAR T cell infusion are linked to the magnitude and speed of the CAR T cell&#xd;
expansion, which is a function of signaling mediated through the costimulatory&#xd;
domain. Having a “druggable” method to provide costimulatory signals could be a&#xd;
strategy to: (i) tune in vivo T cell expansion, (ii) allow the physician to toggle&#xd;
costimulation during periods where it is advantageous to the therapeutic strategy,&#xd;
and (iii) enhance endogenous immune cell anti-tumour activity. A high throughput&#xd;
screen assessing 4000 biologically active compounds for their effect on engineered&#xd;
T cell proliferation identified Ferutinin, a natural small molecule with no known&#xd;
immunomodulatory activity. A small library of Ferutinin analogues (N=25) were&#xd;
synthesized to predict and optimize its biologically active molecular structure(s).&#xd;
Methods: We first assessed the impact of Ferutinin analogues on multiple classes&#xd;
of tumour re-targeting receptors TAC and DAP12 synthetic antigen receptor (SAR)&#xd;
engineered T cell function. We chose the TAC and DAP12 SAR receptor because&#xd;
they mediate T cell activation via natural signalling pathways and include no&#xd;
costimulatory domains. We then developed a high throughput screen (HTS) using&#xd;
luciferase as an indirect measure of TAC T cell number and screened >15,000&#xd;
compounds with known biological activity at McMaster University’s Centre for&#xd;
Microbial and Chemical Biology. Finally, we validated the outcomes of the HTS.&#xd;
Results: Our studies did not find evidence of improved TAC or DAP12 SAR T cell&#xd;
function in the presence of Ferutinin analogues. The HTS did find classes of&#xd;
compounds with characterized costimulatory activity, including&#xd;
immunomodulatory drugs, phorbol esters and SMAC mimetics. 8-&#xd;
Geranyloxypsoralen and BAY 60 6583 demonstrated on-target enhancement of&#xd;
TAC T cell proliferation independent of T cell donor.&#xd;
Conclusions: These findings demonstrate the utility of small molecules as a&#xd;
method to enhance proliferation of engineered T cell products, recapitulating the&#xd;
effects of a costimulatory signal.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">T cells protect the human body by surveilling and removing harmful cells. Scientific&#xd;
advancements have allowed us to re-target T cells to better eliminate cancer; this&#xd;
approach has demonstrated great clinical success for the treatment of blood&#xd;
cancers. Genetic modification strategies to enhance the clinical efficacy of existing&#xd;
re-targeted T cell products have been effective but are associated with toxicities.&#xd;
We propose using a chemical biology approach to enhance the function of modified&#xd;
T cells with small molecules, while potentially mitigating toxicities during&#xd;
treatment. We investigated over 15,000 chemicals compounds to identify&#xd;
candidate(s) that may improve genetically modified T cell function.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Small molecules</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">CAR-T</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Genetic engineering</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">PHARMACOLOGICAL COSTIMULATION OF ENGINEERED T CELLS</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">Delivering Pharmacological Costimulation to Augment the Anti-tumour Activity of Engineered T cells</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>